The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Open accessAbstract
CONTEXT: Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health. OBJECTIVE: To determine whether an N-methyl-D-aspartate-receptor antagonist produces rapid antidepressant effects in subjects with bipolar depression. DESIGN: A randomized, placebo-controlled, double-blind, crossover, add-on study conducted from October 2006 to June 2009. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health, Bethesda, Maryland. Patients Eighteen subjects with DSM-IV bipolar depression (treatment-resistant). INTERVENTIONS: Subjects maintained at therapeutic levels of lithium or valproate received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days 2 weeks apart. The Montgomery-Asberg Depression Rating Scale was used to rate subjects at baseline and at 40, 80, 110, and 230 minutes and on days 1, 2, 3, 7, 10, and 14 postinfusion. MAIN OUTCOME MEASURES: Change in Montgomery-Asberg Depression Rating Scale primary efficacy measure scores. RESULTS: Within 40 minutes, depressive symptoms significantly improved in subjects receiving ketamine compared with placebo (d = 0.52, 95% confidence interval [CI], 0.28-0.76); this improvement remained significant through day 3. The drug difference effect size was largest at day 2 (d = 0.80, 95% CI, 0.55-1.04). Seventy-one percent of subjects responded to ketamine and 6% responded to placebo at some point during the trial. One subject receiving ketamine and 1 receiving placebo developed manic symptoms. Ketamine was generally well tolerated; the most common adverse effect was dissociative symptoms, only at the 40-minute point. CONCLUSION: In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Shortly thereafter, ketamine's robust antidepressant effects were confirmed in treatmentresistant depression (TRD) and bipolar disorder (BD) [5][6][7]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Intravenous ketamine (level 3)477, 478 has rapid onset of efficacy”
The cited source says what the claim attributes to it.
In the citing paper
“However, ketamine’s antidepressant properties are also transient, lasting an average of 1 week following a single infusion10–14 and 18–19 days following repeated infusions.15,16”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [12]
In the citing paper
“Subsequent randomized controlled trials (RCTs) replicated this finding, demonstrating a 60–70% response rate of ketamine in TRD populations.10–14”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [12]
In the citing paper
“Firstly, the suicidal risk was often poorly measured (eg, with one single item of a depression scale).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [8]
In the citing paper
“Thirdly, samples were usually small.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [8]
In the citing paper
“Recently, ketamine has been shown to have a rapid effect on depressive symptoms and suicidal ideation after a single dose.8 9 10 11”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [8]
In the citing paper
“Secondly, response (usually defined as a 50% score reduction on a scale) was the most common outcome rather than remission (that is, complete absence of suicidal ideas).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [8]
In the citing paper
“Results in bipolar disorder—a disorder associated with a high suicidal risk and limited options to treat depression27—are highly encouraging and support two previous small studies.8 28”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [8]
In the citing paper
“A single, intravenous or intranasal sub-anesthetic dose of ketamine, a non-competitive NMDA glutamate receptor channel blocker, produces a rapid onset of antidepressant response that can last several days in the majority of treatment resistant unipolar and bipolar depressed patients participating in a growing number of clinical trials148–150.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [149]
In the citing paper
“In addition to the therapeutic effects of ketamine in major depressed patients, ketamine exerts antidepressant actions in patients suffering with bipolar depression, with a similar response rate 20, 21.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,860
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- [31]First MB Spitzer RL Gibbon M Williams AR Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2001 New York State Psychiatric Institute, Biometrics Research New York, NY
Cited by
Sorted by citations
Items 101–157 of 157
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., O’Loughlin, K., Torjman, M. C., Bernier, M., & Wainer, I. W. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000285 · Cited by 115
Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate
Downey, D., Dutta, A., McKie, S., Dawson, G. R., Dourish, C. T., Craig, K., Smith, M. A., McCarthy, D. J., Harmer, C. J., Goodwin, G. M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.006 · Cited by 116
Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
Stereoselective and regiospecific hydroxylation of ketamine and norketamine
Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.685777 · Cited by 114
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
Self-citationStress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037916 · Cited by 107
Synaptic Mechanisms Regulating Mood State Transitions in Depression
Parekh, P. K., Johnson, S. B., & Liston, C. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110920-040422 · Cited by 101
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Self-citationKadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Self-citationRapid Mood-Elevating Effects of Low Field Magnetic Stimulation in Depression
Rohan, M. L., Yamamoto, R. T., Ravichandran, C. T., Cayetano, K. R., Morales, O. G., Olson, D. P., Vitaliano, G., Paul, S. M., & Cohen, B. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.024 · Cited by 97
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
Self-citationOral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
Ballard, E. D., Luckenbaugh, D. A., Richards, E. M., Walls, T. L., Brutsché, N. E., Ameli, R., Niciu, M. J., Vande Voort, J. L., & Zarate, C. A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.003 · Cited by 80
“…efficacy of ketamine in the treatment of depression (both treatment-resistant major depressive disorder (MDD) and bipolar I or II (BD) depression); results of these studies have been published elsewhere (Diazgranados et al., 2010b; Ibrahim et al., 2012; Zarate et al., 2012; Zarate et al., 2006).”
Self-citationRisks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Ketamine, Sleep, and Depression: Current Status and New Questions
Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0394-z · Cited by 76
Self-citationMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
Self-citationFrye, M. A., Blier, P., & Tye, S. J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000316 · Cited by 75
Tolliver, B. K., DeSantis, S. M., Brown, D. G., Prisciandaro, J. J., & Brady, K. T. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00973.x · Cited by 74
Kaut, O., Schmitt, I., Hofmann, A., Hoffmann, P., Schlaepfer, T. E., Wüllner, U., & Hurlemann, R. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0572-y · Cited by 68
Taylor, M. J., Tiangga, E. R., Mhuircheartaigh, R. N., & Cowen, P. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405359 · Cited by 66
Vande Voort, J. L., Ballard, E. D., Luckenbaugh, D. A., Bernert, R. A., Richards, E. M., Niciu, M. J., Park, L. T., Machado-Vieira, R., Duncan, W. C., & Zarate, C. A. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10440 · Cited by 65
Self-citationTobacco use in bipolar disorder
Thomson, D., Berk, M., Dodd, S., Rapado-Castro, M., Quirk, S. E., Ellegaard, P. K., Berk, L., & Dean, O. M. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.1 · Cited by 63
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
Self-citationWhittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
Li, D.-J., Wang, F.-C., Chu, C.-S., Chen, T.-Y., Tang, C.-H., Yang, W.-C., Chow, P. C.-K., Wu, C.-K., Tseng, P.-T., & Lin, P.-Y. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.008 · Cited by 51
Zanicotti, C. G., Perez, D., & Glue, P. (2012) · Journal of Palliative Medicine · doi:10.1089/jpm.2011.0314 · Cited by 52
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression
Zheng, W., Zhou, Y.-L., Liu, W.-J., Wang, C.-Y., Zhan, Y.-N., Lan, X.-F., Zhang, B., & Ning, Y.-P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.020 · Cited by 44
Fuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40
Neurobiological aspects of suicide and suicide attempts in bipolar disorder
Mathews, D., Richards, E., Niciu, M., Ionescu, D., Rasimas, J., & Zarate, C. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0120-7 · Cited by 39
Self-citationInpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression
Wilkowska, A., Wiglusz, M. S., Gałuszko-Wegielnik, M., Włodarczyk, A., & Cubała, W. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.704330 · Cited by 35
“Ketamine is a novel, effective, and rapid-acting antidepressant in unipolar patients (5, 6) and bipolar treatment resistant depression (7).”
BackgroundKetamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970857 · Cited by 31
Yang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
Are 24-hour motor activity patterns associated with continued rapid response to ketamine?
Duncan Jr, W. C., Slonena, E. E., Hejazi, N. S., Brutsche, N., Park, L. T., Henter, I. D., Ballard, E. D., & Zarate Jr, C. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172089 · Cited by 17
Self-citationProspective association of psychological pain and hopelessness with suicidal thoughts
Ballard, E. D., Farmer, C. A., Gerner, J., Bloomfield-Clagett, B., Park, L. T., & Zarate, C. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.033 · Cited by 16
Self-citationBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Mandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15
“Ketamine is a noncompetitive antagonist to the N-methyl-D-aspartate receptor (NMDAR) shown in numerous studies to alleviate depressive symptoms, even in those with treatment-resistant depression (Diazgranados et al., 2010; Murrough et al., 2013; Bobo et al., 2016).”
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Weiss, M., & Siegmund, W. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.993 · Cited by 13
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
Self-citationBloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
Self-citation
Metadata
- Authors
- Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., Machado-Vieira, R., Manji, H. K., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-08-01
- Volume
- 67
- Issue
- 8
- Pages
- 793
- ISSN
- 0003-990X (ISSN-L)
- PMC
- PMC3000408
- OpenAlex
- W2108403304
- Cited by
- 963
- References
- 50
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 31 · 2023: 40 · 2022: 56 · 2021: 68 · 2020: 76 · 2019: 52 · 2018: 66 · 2017: 55 · 2016: 81 · 2015: 96 · 2014: 73 · 2013: 80 · 2012: 73
- FWCI
- 48.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- bipolar depression, treatment-resistant depression, ketamine, NMDA receptor antagonists, rapid antidepressant effects, intravenous infusion, lithium, valproic acid, manic symptoms
- MeSH terms
- Adolescent, Adult, Aged, Bipolar Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Valproic Acid, N-Methylaspartate, Treatment Outcome, Lithium Compounds, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
